WO2008153129A1 - Agent pour abaisser le taux d'acide urique - Google Patents

Agent pour abaisser le taux d'acide urique Download PDF

Info

Publication number
WO2008153129A1
WO2008153129A1 PCT/JP2008/060845 JP2008060845W WO2008153129A1 WO 2008153129 A1 WO2008153129 A1 WO 2008153129A1 JP 2008060845 W JP2008060845 W JP 2008060845W WO 2008153129 A1 WO2008153129 A1 WO 2008153129A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
uric acid
acid level
lowering
lowering uric
Prior art date
Application number
PCT/JP2008/060845
Other languages
English (en)
Japanese (ja)
Inventor
Satoshi Oda
Kazutaka Shiobara
Yasuhito Yasogi
Kaori Uchino
Nobuko Toyota
Kisaburou Isobe
Tsuyoshi Mizuno
Kumiko Hase
Shin Umeda
Naoki Yajima
Original Assignee
Teijin Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Limited filed Critical Teijin Pharma Limited
Publication of WO2008153129A1 publication Critical patent/WO2008153129A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un nouvel agent pour abaisser un taux d'acide urique ou similaire. De façon précise, l'invention porte sur un agent pour abaisser un taux d'acide urique ou similaire, qui comporte un dérivé à noyau aromatique azoté représenté par la formule (I) ou un sel de celui-ci comme principe actif.
PCT/JP2008/060845 2007-06-14 2008-06-13 Agent pour abaisser le taux d'acide urique WO2008153129A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2007-157336 2007-06-14
JP2007157336 2007-06-14
JP2007259870 2007-10-03
JP2007-259870 2007-10-03
JP2007-315718 2007-12-06
JP2007315718 2007-12-06

Publications (1)

Publication Number Publication Date
WO2008153129A1 true WO2008153129A1 (fr) 2008-12-18

Family

ID=40129732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060845 WO2008153129A1 (fr) 2007-06-14 2008-06-13 Agent pour abaisser le taux d'acide urique

Country Status (2)

Country Link
TW (1) TW200916098A (fr)
WO (1) WO2008153129A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010147133A1 (fr) 2009-06-17 2010-12-23 小野薬品工業株式会社 Nouveau composé imidazopyridine
WO2014183555A1 (fr) 2013-05-13 2014-11-20 上海恒瑞医药有限公司 Dérivé d'acide cycloalkylique, procédé de préparation et utilisation pharmaceutique de celui-ci
US8952177B2 (en) 2013-03-15 2015-02-10 Janssen Pharmaceutica Nv 1,2,6-substituted benzimidazoles as FLAP modulators
US9067917B2 (en) 2013-03-15 2015-06-30 Janssen Pharmaceutica Nv 1,2,5-substituted benzimidazoles as FLAP modulators
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
CN108084153A (zh) * 2017-12-20 2018-05-29 广东赛烽医药科技有限公司 吡啶基硫代乙酸化合物、组合物及其应用
CN110885318A (zh) * 2019-11-28 2020-03-17 苏州大学 苯并恶唑衍生物及其制备方法和应用
CN111943957A (zh) * 2019-05-17 2020-11-17 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107987006B (zh) * 2017-12-20 2021-06-01 华润赛科药业有限责任公司 吲哚类或氮杂吲哚类衍生物、其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5262278A (en) * 1975-11-13 1977-05-23 Hoechst Ag Production of novel imidazole compound and pharmaceutical agent
JPH04211020A (ja) * 1990-02-22 1992-08-03 Ciba Geigy Ag トロンボキサンシンセターゼ阻害剤および／またはトロンボキサンレセプター拮抗剤またはそれらの組合せを用いて血清尿酸を減少させそして／または直腸の尿酸クリアランスを増加させる方法
JPH05155858A (ja) * 1990-02-16 1993-06-22 Lab Up Sa トロンボキサン受容体アンタゴニストである新規ベンズイミダゾールおよびアザベンズイミダゾール誘導体、それらの製造方法、およびそれらを含む合成中間体および薬剤組成物
WO2000003997A1 (fr) * 1998-07-15 2000-01-27 Teijin Limited Derives de thiobenzimidazole
WO2001053291A1 (fr) * 2000-01-17 2001-07-26 Teijin Limited Derives benzimidazoles
WO2001089519A1 (fr) * 2000-05-22 2001-11-29 Nitromed, Inc. Inhibiteurs de thromboxane, compositions, procedes d'utilisation et applications correspondantes
WO2007068621A1 (fr) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Nouveaux dérivés de pyrrole à cycles fusionnés
WO2008045688A1 (fr) * 2006-10-06 2008-04-17 Boehringer Ingelheim International Gmbh Inhibiteurs de chymase

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5262278A (en) * 1975-11-13 1977-05-23 Hoechst Ag Production of novel imidazole compound and pharmaceutical agent
JPH05155858A (ja) * 1990-02-16 1993-06-22 Lab Up Sa トロンボキサン受容体アンタゴニストである新規ベンズイミダゾールおよびアザベンズイミダゾール誘導体、それらの製造方法、およびそれらを含む合成中間体および薬剤組成物
JPH04211020A (ja) * 1990-02-22 1992-08-03 Ciba Geigy Ag トロンボキサンシンセターゼ阻害剤および／またはトロンボキサンレセプター拮抗剤またはそれらの組合せを用いて血清尿酸を減少させそして／または直腸の尿酸クリアランスを増加させる方法
WO2000003997A1 (fr) * 1998-07-15 2000-01-27 Teijin Limited Derives de thiobenzimidazole
WO2001053291A1 (fr) * 2000-01-17 2001-07-26 Teijin Limited Derives benzimidazoles
WO2001089519A1 (fr) * 2000-05-22 2001-11-29 Nitromed, Inc. Inhibiteurs de thromboxane, compositions, procedes d'utilisation et applications correspondantes
WO2007068621A1 (fr) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Nouveaux dérivés de pyrrole à cycles fusionnés
WO2008045688A1 (fr) * 2006-10-06 2008-04-17 Boehringer Ingelheim International Gmbh Inhibiteurs de chymase

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2444401A1 (fr) * 2009-06-17 2012-04-25 ONO Pharmaceutical Co., Ltd. Nouveau composé imidazopyridine
EP2444401A4 (fr) * 2009-06-17 2012-11-07 Ono Pharmaceutical Co Nouveau composé imidazopyridine
US8569504B2 (en) 2009-06-17 2013-10-29 Ono Pharmaceutical Co., Ltd. Imidazopyridine compound
JP5621771B2 (ja) * 2009-06-17 2014-11-12 小野薬品工業株式会社 新規なイミダゾピリジン化合物
WO2010147133A1 (fr) 2009-06-17 2010-12-23 小野薬品工業株式会社 Nouveau composé imidazopyridine
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US9567355B2 (en) 2010-12-22 2017-02-14 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US9453007B2 (en) 2010-12-22 2016-09-27 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US9682972B2 (en) 2013-03-15 2017-06-20 Janssen Pharmaceutica Nv 1,2,5-substituted benzimidazoles as flap modulators
US9089569B2 (en) 2013-03-15 2015-07-28 Janssen Pharmaceutica Nv 1,2,6-substituted benzimidazoles as flap modulators
US9265770B2 (en) 2013-03-15 2016-02-23 Janssen Pharmaceutica Nv 1,2,5-substituted benzimidazoles as FLAP modulators
US9067917B2 (en) 2013-03-15 2015-06-30 Janssen Pharmaceutica Nv 1,2,5-substituted benzimidazoles as FLAP modulators
US8952177B2 (en) 2013-03-15 2015-02-10 Janssen Pharmaceutica Nv 1,2,6-substituted benzimidazoles as FLAP modulators
US9682971B2 (en) 2013-03-15 2017-06-20 Janssen Pharmaceutica Nv 1,2,5-Substituted benzimidazoles as flap modulators
US9695149B2 (en) 2013-03-15 2017-07-04 Janssen Pharmaceutica Nv 1,2,6-substituted benzimidazoles as flap modulators
US9637484B2 (en) 2013-05-13 2017-05-02 Shanghai Hengrui Pharmaceutical Co., Ltd. Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
WO2014183555A1 (fr) 2013-05-13 2014-11-20 上海恒瑞医药有限公司 Dérivé d'acide cycloalkylique, procédé de préparation et utilisation pharmaceutique de celui-ci
CN108084153A (zh) * 2017-12-20 2018-05-29 广东赛烽医药科技有限公司 吡啶基硫代乙酸化合物、组合物及其应用
CN111943957A (zh) * 2019-05-17 2020-11-17 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN110885318A (zh) * 2019-11-28 2020-03-17 苏州大学 苯并恶唑衍生物及其制备方法和应用
CN110885318B (zh) * 2019-11-28 2022-12-23 苏州大学 苯并恶唑衍生物及其制备方法和应用

Also Published As

Publication number Publication date
TW200916098A (en) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2008153129A1 (fr) Agent pour abaisser le taux d'acide urique
WO2007028135A3 (fr) Composes a base d'imidazopyridine
WO2009041705A3 (fr) Composé hétérocyclique à 5 chaînons
WO2008108323A1 (fr) Médicament destiné au traitement de la grippe
WO2005074603A3 (fr) Utilisation d'aminobenzoxazoles comme agents therapeutiques
WO2008110314A8 (fr) Fluoroalkylphénylamidines et leur utilisation comme fongicides
WO2005110410A3 (fr) Inhibiteurs de kinases en tant qu'agents therapeutiques
WO2009020140A1 (fr) Dérivé d'adamantylurée
WO2009156462A3 (fr) Composés organiques
WO2005074642A3 (fr) Composes chimiques
WO2009057079A3 (fr) Nouveaux dérivés de pyrimidine
WO2008110355A8 (fr) Dérivés de quinoléine en tant que fongicides
WO2009051670A3 (fr) Compositions et procédés destinés au traitement de maladies ophtalmiques
WO2009019015A8 (fr) Nouveaux herbicides
WO2009019005A3 (fr) Nouveaux herbicides
WO2008156094A1 (fr) Dérivé de pyridazinone et inhibiteur de la pde le contenant comme ingrédient actif
WO2008128639A8 (fr) Thiadiazolyloxyphénylamidines et leur utilisation comme fongicides
WO2008110280A3 (fr) Phénoxyphénylamidines 3-substituées et leur utilisation comme fongicides
WO2010129918A8 (fr) Promédicaments à base de triptolide
WO2005085236A3 (fr) Inhibiteurs de la caspase et leurs utilisations
WO2008151828A3 (fr) Nouveaux microbiocides
WO2008155666A3 (fr) Dérivés de pyrimidone hétéroarylamide
WO2009127718A3 (fr) Nouveaux microbiocides
WO2009020137A1 (fr) Dérivé d'aminopyrazole amide
WO2009051223A1 (fr) Composition pharmaceutique pour le traitement de la cataracte

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777206

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08777206

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP